|
You are here: Home: BCU 7|2002: Clifford A Hudis,
MD: Select publications
Select publications
Burstein HJ et al. Multicenter Phase II study of trastuzumab
(Herceptin; H) and vinorelbine (Navelbine; N) as first-line therapy
for HER2 overexpressing metastatic breast cancer (HER2+ MBC). Proc
ASCO 2002;Abstract
211.
Chen D et al. Tamoxifen and toremifene cause impairment
of learning and memory function in mice. Pharmacol Biochem
Behav 2002;71(1-2):269-76. No abstract available.
Dowsett M. Overexpression of HER-2 as a resistance mechanism
to hormonal therapy for breast cancer. Endocr Relat Cancer
2001;8(3):191-5. Abstract
Dowsett M et al. HER-2 amplification impedes the antiproliferative
effects of hormone therapy in estrogen receptor-positive primary
breast cancer. Cancer Res 2001;61(23):8452-8. Abstract
Gebauer G et al. Epithelial cells in lymph nodes or bone
marrow do not predict long-term outcome in lymph node-negative breast
cancer patients. Proc ASCO 2002;Abstact
147.
Greenwald P. Cancer prevention clinical trials.
J Clin Oncol 2002;20(18 Suppl):14S-22S. Abstract
Heinemann V et al. Gemcitabine and cisplatin +/- trastuzumab
(Herceptin) in intensively pretreated metastatic breast cancer (MBC).
Proc ASCO 2002;Abstract
2056.
Lee IM et al. Lifetime physical activity and risk of breast
cancer. Br J Cancer 2001;85(7):962-5. Abstract
Ligibel JA and Winer EP. Trastuzumab/chemotherapy combinations
in metastatic breast cancer. Semin Oncol 2002;29(3 Suppl
11):38-43. Abstract
Lipton A et al. Elevated serum Her-2/neu level predicts
decreased response to hormone therapy in metastatic breast cancer.
J Clin Oncol 2002;20(6):1467-72. Abstract
Maunsell E et al. Dietary change after breast cancer:
Extent, predictors, and relation with psychological distress.
J Clin Oncol 2002;20(4):1017-25. Abstract
Moradi T et al. Physical activity and risk for breast
cancer a prospective cohort study among Swedish twins.
Int J Cancer 2002;100(1):76-81. Abstract
Nabholtz JM et al. Phase III trial comparing TAC (docetaxel,
doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin,
cyclophosphamide) in the adjuvant treatment of node-positive breast
cancer (BC) patients: Interim analysis of the BCIRG 001 study.
Proc ASCO 2001;Abstract
141.
Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive
function in breast cancer patients treated with tamoxifen. Breast
Cancer Res Treat 2000;64(2):165-76. Abstract
Piccart M et al. The predictive value of HER2 in breast
cancer. Oncology 2001;61 Suppl 2:73-82. Abstract
Pinto BM, Trunzo JJ, Reiss P, Shiu SY. Exercise participation
after diagnosis of breast cancer: Trends and effects on mood and
quality of life. Psychooncology 2002;11(5):389-400. No
abstract available.
Pinto BM et al. Motivation to modify lifestyle risk behaviors
in women treated for breast cancer. Mayo Clin Proc 2002;77(2):122-9.
Abstract.
Rowan Chlebowski, MD Bradlow HL, Sepkovic DW. Diet and
breast cancer. Ann N Y Acad Sci 2002;963:247-67. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal
antibody against HER2 for metastatic breast cancer that overexpresses
HER2. N Engl J Med 2001;344 (11):783-92. Abstract
Tan LK et al. Occult/micrometastases in axillary lymph
nodes of breast cancer patients are significant: A retrospective
study with long-term follow-up. Proc ASCO 2002;Abstact
146.
Vogel CL et al. Efficacy and safety of trastuzumab as
a single agent in first-line treatment of HER2- overexpressing metastatic
breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
Voorrips LE et al. Intake of conjugated linoleic acid,
fat, and other fatty acids in relation to postmenopausal breast
cancer: The Netherlands Cohort Study on Diet and Cancer.
Am J Clin Nutr 2002;76(4):873-82. Abstract.
Yamauchi H et al. When is a tumor marker ready for prime
time? A case study of c-erbB-2 as a predictive factor in breast
cancer. J Clin Oncol 2001;19(8):2334-56. Abstract
|
